Latest Conference Articles

How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement

How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement

November 13th 2023

AASLD The Liver Meeting

TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.

NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds

NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds

November 12th 2023

AASLD The Liver Meeting

More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.

Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral

Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral

November 11th 2023

AASLD The Liver Meeting

One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.

FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research

FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research

November 10th 2023

AASLD The Liver Meeting

TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.

New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries

New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries

November 10th 2023

AASLD The Liver Meeting

TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.

New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives

New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives

November 10th 2023

AASLD The Liver Meeting

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

Novel Algorithm, FAST-3,  Shows Promise as Noninvasive Classifier for Advanced Fibrosis  in MASLD

Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD

November 10th 2023

AASLD The Liver Meeting

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk

Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk

November 10th 2023

AASLD The Liver Meeting

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization

Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization

November 10th 2023

AASLD The Liver Meeting

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age

Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age

November 10th 2023

AASLD The Liver Meeting

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.